-
1Academic Journal
Authors: G. V. Volynets, A. V. Nikitin, Г. В. Волынец, А. В. Никитин
Source: Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics); Том 65, № 1 (2020); 11-21 ; Российский вестник перинатологии и педиатрии; Том 65, № 1 (2020); 11-21 ; 2500-2228 ; 1027-4065 ; 10.21508/1027-4065-2020-65-1
Subject Terms: дети, дефицит альфа-1-антитрипсина, патофизиология поражения печени, холестаз, фиброз, цирроз, гепатоцеллюлярная карцинома
File Description: application/pdf
Relation: https://www.ped-perinatology.ru/jour/article/view/1052/886; Laurell C.B., Eriksson S. The electrophoretic α1-globulin pattern of serum in α1-antitrypsin deficiency. 1963. COPD 2013; 10 Suppl 1: 3–8. DOI:10.3109/15412555.2013.771956; Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med 1976; 294 (24): 1316–1321. DOI:10.1056/NEJM197606102942404; Campos M.A., Wanner A., Zhang G., Sandhaus R.A. Trends in the diagnosis of symptomatic patients with alpha1-antitrypsin deficiency between 1968 and 2003. Chest 2005; 128 (3): 1179–1186. DOI:10.1378/chest.128.3.1179; Duvoix A., Roussel B.D., Lomas D.A. Molecular pathogenesis of alpha-1-antitrypsin deficiency. Rev Mal Respir 2014; 31 (10): 992–1002. DOI:10.1016/j.rmr.2014.03.015; Ильченко А.А. Болезни желчного пузыря и желчных путей. Руководство для врачей. 2-е изд., перераб. и доп. М.: Медицинское информационное агентство, 2011; 880. [Il’chenko A.A. Diseases of the gallbladder and biliary tract. A guide for doctors. Moscow: Meditsinskoe informatsionnoe agentstvo, 2011; 880. (in Russ.)]; Жигальцова-Кучинская О.А., Сивицкая Л.Н., Даниленко Н.Г., Жигальцов А.М., Нагорнов И.В., Метельский С.М. Дефицит альфа-1-антитрипсина: генетические основы, эпидемиология, значение в развитии бронхолегочной патологии. Вестник Витебского государственного медицинского университета 2015; 14 (6): 39-52. [Zhigaltsova-Kuchinskaya O.A., Sivitskaya L.N., Danilenko N.G., Zhigaltsov A.M., Nagornov I.V., Metelsky S.M. Alpha-1-antitrypsin deficiency: genetic basis, epidemiology, significance in the development of bronchopulmonary pathology. Vestnik Vitebskogo gosudarstvennogo meditsinskogo universiteta 2015; 14 (6): 39–52. (in Russ.)] 7. Колесникова Е.В. Альфа-1-антитрипсиновая недостаточность: Современный взгляд на проблему. Сучасна гастроентерологія 2008; 2: 93–98. [Kolesnikova E.V. Alpha-1-antitrypsin deficiency: A modern view of the problem. Suchasna gastroenterologіya 2008; 2: 93–98. (in Russ.)]; American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168 (7): 818–900. DOI:10.1164/rccm.168.7.818; McLean C., Greene C.M., McElvaney N.G. Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency. Biologics 2009; 3: 63–75.; Teckman J.H., Jain A. Advances in alpha-1-antitrypsin deficiency liver disease. Curr Gastroenterol Rep 2014; 16 (1): 367. DOI:10.1007/s11894-013-0367-8; Stoller J.K., Aboussouan L.S. A review of α1-antitrypsin deficiency. Am J Respir Crit Care Med 2012; 185 (3): 246–259. DOI:10.1164/rccm.201108-1428CI; Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ 1997; 75 (5): 397–415.; Crowther D.C., Belorgey D., Miranda E., Kinghorn K.J., Sharp L.K., Lomas D.A. Practical genetics: alpha-1-antitrypsin deficiency and the serpinopathies. Eur J Hum Genet 2004; 12 (3): 167–172. DOI:10.1038/sj.ejhg.5201127; Davis I.D., Burke B., Freese D., Sharp H.L., Kim Y. The pathologic spectrum of the nephropathy associated with alpha 1-antitrypsin deficiency. Hum Pathol 1992; 23 (1): 57– 62. DOI:10.1016/0046-8177(92)90012-r; Fregonese L., Stolk J., Frants R.R., Veldhuisen B. Alpha-1 antitrypsin Null mutations and severity of emphysema. Respir Med 2008; 102 (6): 876–884. DOI:10.1016/j. rmed.2008.01.009; Fairbanks K.D., Tavill A.S. Liver disease in alpha 1-antitrypsin deficiency: a review. Am J Gastroenterol 2008; 103 (8): 2136–2141. DOI:10.1111/j.1572-0241.2008.01955.x; Molloy K., Hersh C.P., Morris V.B., Carroll T.P., O’Connor C.A., Lasky-Su J.A. et al. Clarification of the risk of chronic obstructive pulmonary disease in α1-antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit Care Med 2014; 189 (4): 419–427. DOI:10.1164/rccm.201311-1984OC; Lomas D.A., Evans D.L., Finch J.T., Carrell R.W. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature 1992; 357 (6379): 605–607. DOI:10.1038/357605a0; Lomas D.A. Twenty years of polymers: A personal perspective on alpha-1 antitrypsin deficiency. COPD 2013; 10 (Suppl 1): 17–25. DOI:10.3109/15412555.2013.764401; Teckman J.H. Liver disease in alpha-1 antitrypsin deficiency: current understanding and future therapy. COPD 2013; 10 (Suppl 1): 35–43. DOI:10.3109/15412555.2013.765839; Rakela J., Goldschmiedt M., Ludwig J. Late manifestation of chronic liver disease in adults with alpha-1-antitrypsin deficiency. Dig Dis Sci 1987; 32 (12): 1358–1362. DOI:10.1007/bf01296661; de Serres F., Blanco I. Role of alpha-1 antitrypsin in human health and disease. J Intern Med 2014; 276 (4): 311–335. DOI:10.1111/joim.12239; Sharp H.L., Bridges R.A., Krivit W., Freier E.F. Cirrhosis associated with alpha-1-antitrypsin deficiency: a previously unrecognized inherited disorder. J Lab Clin Med 1969; 73 (6): 934–939.; Sharp H.L. History of the first description of childhood liver disease in AATD. COPD 2013; 10 (Suppl 1): 13–16. DOI:10.3109/15412555.2013.766165; Francavilla R., Castellaneta S.P., Hadzic N., Chambers S.M., Portmann B., Tung J. et al. Prognosis of alpha-1-antitrypsin deficiency-related liver disease in the era of paediatric liver transplantation. J Hepatol 2000; 32 (6): 986–992. DOI:10.1016/s0168-8278(00)80103-8; Kemmer N., Kaiser T., Zacharias V., Neff G.W. Alpha-1-antitrypsin deficiency: outcomes after liver transplantation. Transplant Proc 2008; 40 (5): 1492–1494. DOI:10.1016/ j.transproceed.2008.02.075; Sveger T., Eriksson S. The liver in adolescents with alpha 1- antitrypsin deficiency. Hepatol 1995; 22 (2): 514–517. DOI:10.1002/hep.1840220221; Teckman J.H., Gilmore R., Perlmutter D.H. Role of ubiquitin in proteasomal degradation of mutant alpha(1)-antitrypsin Z in the endoplasmic reticulum. Am J Physiol Gastrointest Liver Physiol 2000; 278 (1): G39–48. DOI:10.1152/ajpgi.2000.278.1.G39; Lindblad D., Blomenkamp K., Teckman J. Alpha-1-antitrypsin mutant Z protein content in individual hepatocytes correlates with cell death in a mouse model. Hepatol 2007; 46 (4): 1228–1235. DOI:10.1002/hep.21822; Teckman J.H., Rosenthal P., Abel R., Bass L.M., Michail S., Murray K.F. et al. Baseline analysis of a young alpha-1-antitrypsin deficiency liver disease cohort reveals frequent portal hypertension. J Pediatr Gastroenterol Nutr 2015; 61 (1): 94–101. DOI:10.1097/MPG.0000000000000753. 0000000000000753 31. Teckman J.H., Perlmutter D.H. Retention of mutant alpha(1)-antitrypsin Z in endoplasmic reticulum is associated with an autophagic response. Am J Physiol Gastrointest Liver Physiol 2000; 279 (5): 961–974. DOI:10.1152/ajpgi.2000.279.5.G961; Sifers R.N. Medicine. Clearing conformational disease. Science 2010; 329 (5988): 154–5. DOI:10.1126/science.1192681; Sifers R.N. Resurrecting the protein fold for disease intervention. Chem Biol 2013; 20 (3): 298–300. DOI:10.1016/j. chembiol.2013.03.002; Perlmutter D.H. Alpha-1-antitrypsin deficiency: importance of proteasomal and autophagic degradative pathways in disposal of liver disease-associated protein aggregates. Annu Rev Med 2011; 62: 333–345. DOI:10.1146/annurev-med-042409-151920; Teckman J.H., Perlmutter D.H. The endoplasmic reticulum degradation pathway for mutant secretory proteins alpha1-antitrypsin Z and S is distinct from that for an unassembled membrane protein. J Biol Chem 1996; 271 (22): 13215–13220. DOI:10.1074/jbc.271.22.13215; Sifers R.N. Intracellular processing of alpha1-antitrypsin. Proc Am Thorac Soc 2010; 7 (6): 376–380. DOI:10.1513/ pats.201001-011AW; Hidvegi T., Ewing M., Hale P., Dippold C., Beckett C., Kemp C. et al. An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science 2010; 329 (5988): 229–232. DOI:10.1126/science.1190354; Kaushal S., Annamali M., Blomenkamp K., Rudnick D., Halloran D., Brunt E.M. et al. Rapamycin reduces intrahepatic alpha-1-antitrypsin mutant Z protein polymers and liver injury in a mouse model. Exp Biol Med (Maywood) 2010; 235 (6): 700–709. DOI:10.1258/ebm.2010.009297; Pastore N., Blomenkamp K., Annunziata F., Piccolo P., Mithbaokar P., Maria Sepe R. et al. Gene transfer of master autophagy regulator TFEB results in clearance of toxic protein and correction of hepatic disease in alpha- 1-anti-trypsin deficiency. EMBO Mol Med 2013; 5 (3): 397–412. DOI:10.1002/emmm.201202046; Marcus N.Y., Blomenkamp K., Ahmad M., Teckman J.H. Oxidative stress contributes to liver damage in a murine model of alpha-1-antitrypsin deficiency. Exp Biol Med (Maywood) 2012; 237 (10): 1163–1172. DOI:10.1258/ebm.2012.012106; Teckman J.H., Mangalat N. Alpha-1 antitrypsin and liver disease: mechanisms of injury and novel interventions. Expert Rev Gastroenterol Hepatol 2015; 9 (2): 261–268. DOI:10.1586/17474124.2014.943187.; Kalsheker N.A. alpha1-Antitrypsin deficiency: best clinical practice. J Clin Pathol 2009; 62: (10): 865–869. DOI:10.1136/jcp.2008.063495; Moyer V., Freese D.K., Whitington P.F., Olson A.D., Brewer F., Colletti R.B. et al. Guideline for the evaluation of cholestatic jaundice in infants: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2004; 39 (2): 115–128. DOI:10.1097/00005176-200408000-00001; Dawwas M.F., Davies S.E., Griffiths W.J., Lomas D.A., Alexander G.J. Prevalence and risk factors for liver involvement in individuals with PiZZ-related lung disease. Am J Respir Crit Care Med 2013; 187 (5): 502–508. DOI:10.1164/rccm.201204-0739OC; Clark V.C., Dhanasekaran R., Brantly M., Rouhani F., Schreck P., Nelson D.R. Liver test results do not identify liver disease in adults with α(1)-antitrypsin deficiency. Clin Gastroenterol Hepatol 2012; 10 (11): 1278–1283. DOI:10.1016/j.cgh.2012.07.007; Rudnick D.A., Perlmutter D.H. Alpha-1-antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in genetic liver disease. Hepatol 2005; 42 (3): 514–521. DOI:10.1002/ hep.20815; Ebell M.H., Siwek J., Weiss B.D., Woolf S.H., Susman J., Ewigman B. et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. Am Fam Physician 2004; 69 (3): 548–556.; De Tommaso A.M., Rossi C.L., Escanhoela C.A., Serra H.G., Bertuzzo C.S., Hessel G. Diagnosis of alpha-1-antitrypsin deficiency by DNA analysis of children with liver disease. Arq Gastroenterol 2001; 38 (1): 63–68.; Filipponi F., Soubrane O., Labrousse F., Devictor D., Bernard O., Valayer J. et al. Liver transplantation for end-stage liver disease associated with alpha-1-antitrypsin deficiency in children: pretransplant natural history, timing and results of transplantation. J Hepatol 1994; 20 (1): 72–78. DOI:10.1016/s0168-8278(05)80469-6; Stoller J.K., Brantly M. The challenge of detecting alpha-1 antitrypsin deficiency. COPD 2013; 10 (Suppl 1): 26–34. DOI:10.3109/15412555.2013.763782; Silverman E.K., Sandhaus R.A. Clinical practice. Alpha1-antitrypsin deficiency. N Engl J Med 2009; 360 (26): 2749– 2757. DOI:10.1056/NEJMcp0900449; Sveger T., Thelin T., McNeil T.F. Young adults with alpha 1-antitrypsin deficiency identified neonatally: their health; knowledge about and adaptation to the high-risk condition. Acta Paediatr 1997; 86 (1): 37–40. DOI:10.1111/j.16512227.1997.tb08828.x; Coors M.E., Moseley R., McGorray S. Informed consent process in Alpha-1 testing of atrisk children: views of parents and adults tested as children. COPD 2011; 8 (1): 30–38. DOI:10.3109/15412555.2010.541958; Harada K., Ohba K., Ozaki S., Isse K., Hirayama T., Wada A. et al. Peptide antibiotic human beta-defensin-1 and -2 contribute to antimicrobial defense of the intrahepatic biliary tree. Hepatol 2004; 40 (4): 925–932. DOI:10.1002/hep.20379; Sveger T., Thelin T., McNeil T.F. Neonatal alpha1-antitrypsin screening: parents’ views and reactions 20 years after the identification of the deficiency state. Acta Paediatr 1999; 88 (3): 315–318. DOI:10.1080/08035259950170097 56. Bakula A., Socha P., Pawlowska J., Teisseyre M., Jankowska I., Kalicinski P. Good and bad prognosis of alpha-1-antitrypsin deficiency in children: when to list for liver transplantation. Transplant Proc 2007; 39 (10): 3186–3188. DOI:10.1016/j. transproceed.2007.09.046; Jain A.B., Patil V., Sheikh B., Apostolakos M., Ryan C., Kashyap R. et al. Effect of liver transplant on pulmonary functions in adult patients with alpha 1 antitrypsin deficiency: 7 cases. Exp Clin Transplant 2010; 8 (1): 4–8.; Vennarecci G., Gunson B.K., Ismail T., Hübscher S.G., Kelly D.A., McMaster P. et al. Transplantation for end stage liver disease related to alpha 1 antitrypsin. Transplant 1996; 61 (10): 1488–1495. DOI:10.1097/00007890199605270-00014; Fromer L. Improving diagnosis and management of alpha-1 antitrypsin deficiency in primary care: translating knowledge into action. COPD 2010; 7 (3): 192–198. DOI:10.3109/15412555.2010.482577; Taliercio R.M., Chatburn R.L., Stoller J.K. Knowledge of alpha-1 antitrypsin deficiency among internal medicine house officers and respiratory therapists: results of a survey. Respir Care 2010; 55 (3): 322–327.; Srivastava A. Progressive familial intrahepatic cholestasis. J Clin Exp Hepatol 2014; 4 (1): 25–36. DOI:10.1016/j. jceh.2013.10.005; Campos M., Shmuels D., Walsh J. Detection of alpha-1 antitrypsin deficiency in the US. Am J Med 2012; 125 (7): 623– 624. DOI:10.1016/j.amjmed.2011.12.014; Aboussouan L.S., Stoller J.K. Detection of alpha-1 antitrypsin deficiency: a review. Respir Med 2009; 103 (3): 335–341. DOI:10.1016/j.rmed.2008.10.006 64. Bals R., Koczulla R., Kotke V., Andress J., Blackert K., Vogelmeier C. Identification of individuals with alpha-1-antitrypsin deficiency by a targeted screening program. Respir Med 2007; 101 (8): 1708–1714. DOI:10.1016/j. rmed.2007.02.024; Hogarth D.K., Rachelefsky G. Screening and familial testing of patients for alpha 1-antitrypsin deficiency. Chest 2008; 133 (4): 981–988. DOI:10.1378/chest.07-1001; Thelin T., Sveger T., McNeil T.F. Primary prevention in a high risk group: smoking habits in adolescents with homozygous alpha1antitrypsin deficiency (ATD). Acta Paediatr 1996; 85 (10): 1207–1212. DOI:10.1111/j.1651-2227.1996.tb18230.x; Seersholm N., Wencker M., Banik N., Viskum K., Dirksen A., Kok-Jensen A. et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J 1997; 10 (10): 2260–2263. DOI:10.1183/09031936.97.10102260; Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998; 158L (1): 49–59. DOI:10.1164/ajrccm.158.1.9712017; Wencker M., Banik N., Buhl R., Seidel R., Konietzko N. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-ATstudy group. Eur Respir J 1998; 11 (2): 428–433. DOI:10.1183/09031936.98.11020428; Dimmick J.E. Intrahepatic bile duct paucity and cytomegalovirus infection. Pediatr Pathol 1993; 13 (6): 847–852.; Dirksen A., Piitulainen E., Parr D.G., Deng C., Wencker M., Shaker SB. et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J 2009; 33 (6): 1345–1353. DOI:10.1183/09031936.00159408
-
2Academic Journal
Authors: M. Yu. Pervakova, S. V. Lapin, E. A. Surkova, O. Yu. Tkachenko, A. I. Budkova, V. I. Guseva, O. N. Titova, V. L. Emanuel, Areg A. Totolian, М. Ю. Первакова, С. В. Лапин, Е. А. Суркова, О. Ю. Ткаченко, А. И. Будкова, В. И. Гусева, О. Н. Титова, В. Л. Эмануэль, Арег А. Тотолян
Source: Medical Immunology (Russia); Том 18, № 6 (2016); 537-544 ; Медицинская иммунология; Том 18, № 6 (2016); 537-544 ; 2313-741X ; 1563-0625 ; 10.15789/1563-0625-2016-6
Subject Terms: дефицит альфа-1-антитрипсина, alpha-1-antitrypsin, cytokine, alpha-1-antitrypsin phenotype, alpha-1-antitrypsin deficiency, альфа-1-антитрипсин, цитокин, фенотип альфа-1-антитрипсина
File Description: application/pdf
Relation: https://www.mimmun.ru/mimmun/article/view/1134/888; Шевченко О.П. Белки острой фазы воспаления. Лаборатория, 1996, № 1. С. 10-17. [Shevchenko O.P. Acute phase proteins. Laboratoriya = Laboratory, 1996, no. 1, pp. 10-17. (In Russ.]); Stoller J.K., Lacbawan F.L., Aboussouan L.S. Alpha-1 antitrypsin deficiency. Gene reviews, 2006.; Lockett A.D., van Demark M., Gu Y., Schweitzer K.S., Sigua N., Kamocki K., Fijalkowska I., Garrison J., Fisher A.J., Serban K., Wise R.A., Flotte T.R., Mueller C., Presson R.G.Jr., Petrache H.I., Tuder R.M., Petrache I. Effect of cigarette smoke exposure and structural modifications on the alpha-1 Antitrypsin interaction with caspases. Mol. Med., 2012, Vol. 18, pp. 445-454.; Feng Y., Xu J., Zhou Q., Wang R., Liu N., Wu Y., Yuan H., Che H. Alpha-1 Antitrypsin prevents the development of preeclampsia through suppression of oxidative stress. Front Physiol., 2016, Vol. 7, p. 176.; Stockley R.A. The multiple facets of alpha-1-antitrypsin. Ann. Transl. Med., 2015, Vol. 3, no. 10, p. 130.; Zampronio A.R., Soares D.M., Souza G.E. Central mediators involved in the febrile response: effects of antipyretic drugs. Temperature (Austin), 2015, Vol. 2, no. 4, pp. 506-521.; Koo J.B., Han J.S. Cigarette smoke extract-induced interleukin-6 expression is regulated by phospholipase D1 in human bronchial epithelial cells. J. Toxicol. Sci., 2016, Vol. 41, no. 1, pp. 77-89.; de Carvalho F.O., Felipe F.A., de Melo Costa A.C., Teixeira L.G., Silva É.R., Nunes P.S., Shanmugam S., de Lucca Junior W., Quintans J.S., de Souza Araújo A.A. Inflammatory mediators and oxidative stress in animals subjected to smoke inhalation: a systematic review. Lung, 2016.; Ansarin K., Rashidi F., Namdar H., Ghaffari M., Sharifi A. Echocardiographic evaluation of the relationship between inflammatory factors (IL6, TNFalpha, hs-CRP) and secondary pulmonary hypertension in patients with COPD. A Cross Sectional Study. Pneumologia, 2015, Vol. 64, no. 3, pp. 31-35.; Chen Z., Shao X., Dou X., Zhang X., Wang Y., Zhu C., Hao C., Fan M., Ji W., Yan Y. Role of the mycoplasma pneumoniae/interleukin-8/neutrophil axis in the pathogenesis of pneumonia. PLoS One, 2016, Vol. 11, no. 1, p. e0146377.; Majak P. Tumor necrosis factor alpha as an asthma biomarker in early childhood. Pneumonol. Alergol. Pol., 2016, Vol. 84, no. 3, pp. 143-144.; Cosmi L., Liotta F., Annunziato F. Th17 regulating lower airway disease. Curr Opin Allergy Clin. Immunol., 2016, Vol. 16, no. 1, pp. 1-6.; Miossec P., Korn T., Kuchroo V.K. Interleukin-17 and type 17 helper T cells. N. Engl. J. Med., 2009, Vol. 361, no. 9, pp. 888-898.; Ortiz G, Salica J.P., Chuluyan E.H., Gallo J.E. Diabetic retinopathy: could the alpha-1 antitrypsin be a therapeutic option? Biol. Res., 2014, Vol. 47, p. 58.; Lewis E.C., Shapiro L., Bowers O.J., Dinarello C.A. Alpha1-antitrypsin monotherapy prolongs islet allograſt survival in mice. Proc. Natl. Acad. Sci. USA, 2005, Vol. 102, no. 34, pp. 12153-12158.; Subramaniyam D., Virtala R., Pawłowski K., Clausen I.G., Warkentin S., Stevens T., Janciauskiene S. TNF-alpha-induced self expression in human lung endothelial cells is inhibited by native and oxidized alpha1-antitrypsin. Int. J. Biochem. Cell Biol., 2008, Vol. 40, no. 2, pp. 258-271.; Bergin D.A., Reeves E.P., Hurley K., Wolfe R., Jameel R., Fitzgerald S., McElvaney N.G. The circulating proteinase inhibitor alpha-1 antitrypsin regulates neutrophil degranulation and autoimmunity. Sci. Transl. Med., 2014, Vol. 6, no. 217, p. 217ra1.; Pott G.B., Chan E.D., Dinarello C.A., Shapiro L. Alpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood. J. Leukoc. Biol., 2009, Vol. 85, no. 5, pp. 886-895.; Subramanian S., Shahaf G., Ozeri E., Miller L.M., Vandenbark A.A., Lewis E.C., Offner H. Sustained expression of circulating human alpha-1 antitrypsin reduces inflammation, increases CD4+FoxP3+ Treg cell population and prevents signs of experimental autoimmune encephalomyelitis in mice. Metab. Brain Dis., 2011, Vol. 26, no. 2, pp. 107-113.; Stone H., McNab G., Wood A.M., Stockley R.A., Sapey E. Variability of sputum inflammatory mediators in COPD and alpha1-antitrypsin deficiency. Eur. Respir. J., 2012, Vol. 40, no. 3, pp. 561-569.; Seixas S., Garcia O., Trovoada M.J., Santos M.T., Amorim A., Rocha J. Patterns of haplotype diversity within the serpin gene cluster at 14q32.1: insights into the natural history of the alpha1-antitrypsin polymorphism. Hum. Genet., 2001, Vol. 108, no. 1, pp. 20-30.; Keren D.F. Protein electrophoresis in clinical diagnosis. Ed. A. London, 2003, pp. 71-77.; Salahuddin P. Genetic variants of alpha1-antitrypsin. Curr. Protein Pept. Sci., 2010, Vol. 11, no. 2, pp. 101-117.; Olfert I.M., Malek M.H., Eagan T.M., Wagner H., Wagner P.D. Inflammatory cytokine response to exercise in alpha-1-antitrypsin deficient COPD patients ‘on’ or ‘off’ augmentation therapy. BMC Pulm. Med., 2014, Vol. 14, p. 106.; Pervakova M.Yu., Emanuel V.L., Titova O.N., Lapin S.V., Mazurov V.I., Belyaeva I.B., Chudinov A.L., Blinova T.V., Surkova E.A. The diagnostic value of alpha-1-antitrypsin phenotype in Patients with granulomatosis with polyangiitis. International Journal of Rheumatology, 2016, pp. 1-5.; Pervakova M.Y., Emanuel V.L., Surkova E.A., Mazing A.V., Lapin S.V., Kovaleva I.S., Sysoeva S.N. The comparison of techniques of electrophoresis, immune turbidynamic measurement and phenotyping of alpha-1-antitrypsin for diagnostic of alpha-1-antitrypsin insufficiency. Clin. Lab. Diagn., 2015, Vol. 10, pp. 28-32.; Mahr A.D., Edberg J.C., Stone J.H., Hoffman G.S., St Clair E.W., Specks U., Dellaripa P.F., Seo P., Spiera R.F., Rouhani F.N., Brantly M.L., Merkel P.A. Alpha(1)-antitrypsin deficiency-related alleles Z and S and the risk of Wegener’s granulomatosis. Arthritis Rheum., 2010, Vol. 62, no. 12, pp. 3760-3767.; American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am. J. Respir. Crit. Care Med., 2003, Vol. 168, no. 7, pp. 818-900.; Duan M.C., Zhang J.Q., Liang Y., Liu G.N., Xiao J., Tang H.J., Liang Y. Infiltration of IL-17-producing T cells and Treg cells in a mouse model of smoke-induced emphysema. Inflammation, 2016.; Singh D. Chronic Obstructive Pulmonary Disease, Neutrophils and Bacterial Infection: A complex web involving IL-17 and IL-22 unravels. EBioMedicine, 2015, Vol. 2, no. 11, pp. 1580-1581.; Chen Q.R., Wang L.F., Xia S.S., Zhang Y.M., Xu J.N., Li H., Ding Y.Z. Role of interleukin-17A in early graſt rejection aſter orthotopic lung transplantation in mice. J. Thorac. Dis., 2016, Vol. 8, no. 6, pp. 1069-1079.; Bergin D.A., Reeves E.P., Meleady P., Henry M., McElvaney O.J., Carroll T.P., Condron C., Chotirmall S.H., Clynes M., O’Neill S.J., McElvaney N.G. Alpha-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. J Clin. Invest., 2010, Vol. 120, no. 12, pp. 4236-4250.; Aldonyte R., Eriksson S., Piitulainen E., Wallmark A., Janciauskiene S. Analysis of systemic biomarkers in COPD patients. COPD, 2004, Vol. 1, no. 2, pp. 155-164.; Honda K., Wada H., Nakamura M., Nakamoto K., Inui T., Sada M., Koide T., Takata S., Yokoyama T., Saraya T., Kurai D., Ishii H., Goto H., Takizawa H. IL-17A synergistically stimulates TNF-alpha-induced IL-8 production in human airway epithelial cells: A potential role in amplifying airway inflammation. Exp. Lung. Res., 2016, Vol. 42, no. 4, pp. 205-216.; https://www.mimmun.ru/mimmun/article/view/1134
-
3Academic Journal
Source: Наука и здравоохранение.
Subject Terms: alpha-1 antitrypsin deficiency, диагностика, 3. Good health, chronic obstructive pulmonary disease, генетика, diagnostics, альфа-1-антитрипсина, альфа-1-антитрипсин, альфа-1-антитрипсин тапшылығы, alpha-1 antitrypsin, genetics, өкпенің созылмалы обструктивті ауруы, дефицит альфа-1-антитрипсина, хроническая обструктивная болезнь легких
-
4Academic Journal
Authors: Svetlana I. Melnik, Nikolay N. Vlasov, Marina V. Pinevskaya, Elena A. Orlova, Svetlana V. Starevskaya, Irina Y. Melnikova, С. И. Мельник, Н. Н. Власов, М. В. Пиневская, Е. А. Орлова, С. В. Старевская, И. Ю. Мельникова
Source: Current Pediatrics; Том 15, № 6 (2016); 619-624 ; Вопросы современной педиатрии; Том 15, № 6 (2016); 619-624 ; 1682-5535 ; 1682-5527
Subject Terms: цирроз, alpha-1 antitrypsin deficiency, emphysema, cirrhosis, дефицит альфа-1-антитрипсина, эмфизема
File Description: application/pdf
Relation: https://vsp.spr-journal.ru/jour/article/view/1701/669; Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ. 1997;75(5):397–415.; Основы клинической гепатологии. Заболевания печени и билиарной системы. Учебное пособие для системы последипломного образования врачей / Под ред. В.Г. Радченко, А.В. Шаброва, Е.Н. Зиновьева. — СПб.: Диалект; М.: БИНОМ; 2005. — 862 с. [Osnovy klinicheskoi gepatologii. Zabolevaniya pecheni i biliarnoi sistemy. Uchebnoe posobie dlya sistemy poslediplomnogo obrazovaniya vrachei. Ed by Radchenko V.G., Shabrov A.V., Zinov’ev E.N. St. Petersburg: Dialekt; Moscow: BINOM; 2005. 862 p. (In Russ).]; Жигальцова-Кучинская А., Сивицкая Л.Н., Даниленко Н.Г. и др. Дефицит альфа-1- антитрипсина: генетические основы, эпидемиология, значение в развитии бронхо- легочной патологии // Вестник Витебского государственного медицинского университета. — 2015. — Т. 14. — № 6 — С. 39–52. [Zhigaltsova-Kuchinskaya OA, Sivitskaya LN, Danilenko NG, et al. Alpha-1-antitrypsin deficiency: genetic fundamentals, epidemiology, role in the development of bronchopulmonary pathology. Vestnik Vitebskogo gosudarstvennogo meditsinskogo universiteta. 2015;14(6):39–52. (In Russ).]; Колесникова Е.В. Альфа-1-антитрипсиновая недостаточность: Современный взгляд на проблему // Сучасна гастроентерологія. — 2008. — № 2 — С. 93–98. [Kolesnikova EV. Al’fa-1-antitripsinovaya nedostatochnost’: Sovremennyi vzglyad na problemu. Contemporary gastroenterology. 2008;(2):93–98. (In Russ).]; American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818–900. doi:10.1164/rccm.168.7.818.; Churg A, Wang X, Wang RD, et al. 1-Antitrypsin suppresses TNF- and MMP-12 production by cigarette smoke-stimulated macrophages. Am J Respir Cell Mol Biol. 2007;37(2):144– 151. doi:10.1165/rcmb.2006-0345OC.; Sharp HL. Alpha-1-antitrypsin deficiency. Hosp Pract. 1971; 6(5):83–96. doi:10.1080/21548331.1971.11706032.; who.int [Internet]. International statistical classification of dise ases and related health problems 10th revision [cited 2016 Nov 9]. Available from: http://apps.who.int/classifications/icd10/browse/2016/en.; europeanlung.org [интернет]. Европейский пульмонологический фонд. Дефицит альфа1-антитрипсина [доступ от 21.10.2016]. Доступ по ссылке http://www.europeanlung.org/assets/files/ru/publications/alpha1-anti-trypsin-ru.pdf.; Hutchinson DCS. Аlpha-1-Antitrypsin deficiency in Europe: geographical distribution of Pi types S and Z. Respir Med. 1998; 92(3):367-377. doi:10.1016/S0954-6111(98)90278-5.; Laurell CB, Eriksson S. The electrophoretic pattern alpha-1-globulin pattern of serum in alpha-l-antitrypsin deficiency. Scan J Clin Lab Invest. 1963;15(2):132–140. doi:10.3109/00365516309051324.; Pariente EA, Degott C, Martin JP, et al. Hepatocytic PAS-positive diastase-resistance inclusions in the absence of alpha-1-antitrypsin deficiency — high prevalence in alcoholic cirrhosis. Am J Clin Pathol. 1981;76(3):299-302. doi:10.1093/ajcp/76.3.299.; Протеолиз в норме и при патологии / Под ред. К.Н. Веремеенко, О.П. Голобородько, А.И. Кизим. — Киев: Здоров’я; 1988. — 199 с. [Proteoliz v norme i pri patologii. Ed by Veremeenko K.N., Goloborod’ko O.P., Kizim A.I. Kiev: Zdorov’ya; 1988. 199 p. (In Russ).]; Дидковский Н.А., Жарова М.А. Значение наследственных факторов в развитии эмфиземы легких // Терапевтический архив. — 2006. — Т. 78. — № 3 — С. 70–74. [Didkovsky NA, Zharova MA. The role of hereditary factors in development of pulmonary emphysema. Ter Arkh. 2006;78(3):70–74. (In Russ).]; Веремеенко К.Н. Ферменты протеолиза и их ингибиторы в медицинской практике. — Киев; 1971. — 216 с. [Veremeenko KN. Fermenty proteoliza i ikh ingibitory v meditsinskoi praktike. Kiev; 1971. 216 p. (In Russ).]; Hubbard RC, Crystal RG. Strategies for aerosol therapy of alpha 1-antitrypsin deficiency by the aerosol route. Lung. 1990;168 Suppl:565–578. doi:10.1007/bf02718179.; Crowther DC, Belorgey D, Miranda E, et al. Practical genetics: alpha-1-antitrypsin deficiency and the serpinopathies. Eur J Hum Genet. 2004;12(3):167–172. doi:10.1038/sj.ejhg.5201127.; Шапошникова Н.А., Шулятьев И.С., Варванина Г.Г., Дроздов В.Н. Клиническое значение наследственного и приобретенного дефицита альфа-1-антитрипсина у больных циррозом печени и болезнью Вильсона-Коновалова // Лабораторная служба. — 2010. — № 10 — С. 12–16. [Shaposhnikova NA, Shulyat’ev IS, Varvanina GG, Drozdov VN. Klinicheskoe znachenie nasledstvennogo i priobretennogo defitsita al’fa-1-antitripsina u bol’nykh tsirrozom pecheni i bolezn’yu Vil’sona-Konovalova. Laboratornaya sluzhba. 2010; (10):12–16. (In Russ).]; Бродская О.Н. Наследственная недостаточность 1-антитрипсина // Практическая пульмонология. — 2008. — № 4 — С. 58–59. [Brodskaya ON. Nasledstvennaya nedostatochnost’ 1-antitripsina. Prakticheskaya pul’monologiya. 2008;(4):58–59. (In Russ).]; Аверьянов А.В., Поливанова А.Э. Дефицит 1-антитрипсина и хроническая обструктивная болезнь легких // Пульмонология. — 2007. — № 3 — С. 103–109. [Averyanov AV, Polivanova AE. Alfa-1-antitripsin deficiency and chronic obstrictivc pulmonary disease. Pul’monologiya. 2007;(3):103–109. (In Russ).]; Castaldi PJ, DeMeo DL, Kent DM, et al. Development of predictive models for airflow obstruction in alpha-1-antitrypsin deficiency. Am J Epidemiol. 2009;170(8):1005–1013. doi:10.1093/aje/kwp216.; Davis ID, Burke B, Freese D, et al. The pathologic spectrum of the nephropathy associated with 1-antitrypsin deficiency. Hum Pathol. 1992;23(1):57–62. doi:10.1016/0046- 8177(92)90012-r.; Churg A, Wang X, Wang RD, et al. Alpha1-antitrypsin suppresses TNF-alpha and MMP-12 production by cigarette smoke-stimulated macrophages. Am J Respir Cell Mol Biol. 2007;37(2):144–151. doi:10.1165/rcmb.2006-0345OC.; Видаль Р., Бланко И., Касас Ф. и др. Рекомендации по диагностике и ведению больных с дефицитом 1-антитрипсина Испанского общества пульмонологии и торакальной хирургии (SEPAR) // Пульмонология. — 2008. — № 1 — С. 14–28. [Vidal R, Blanco I, Casas F, et al. The National Alpha-1 Antitrypsin Registry Committee Guidelines for the diagnosis and management of alpha-1-antitrypsin deficiency of SEPAR. Pul’monologiya. 2008;(1):14–28. (In Russ).]; Назаров П.Г. Реактанты острой фазы воспаления.— СПб.: Наука; 2001. — 423 с. [Nazarov PG. Reaktanty ostroi fazy vospaleniya. St. Petersburg: Nauka; 2001. 423 p. (In Russ).]; Tanash HA, Nilsson PM, Nilsson JA, et al. Survival in severe alpha-1-antitrypsin deficiency (PiZZ). Respir Res. 2010;11:44. doi:10.1186/1465-9921-11-44.; Bornhorst J, Calderon F, Procter M, et al. Genotypes and serum concentrations of human alpha-1-antitrypsin “P” protein variants in a clinical population. J Clin Pathol. 2007;60(10):1124–1128. doi:10.1136/jcp.2006.042762.; Elzouki AN, Segelmark M, Wieslander J, Eriksson S. Strong link between the alpha 1- antitrypsin PiZ allele and Wegener’s granulomatosis. J Intern Med. 1994;236(5):543–548. doi:10.1111/j.1365-2796.1994.tb00842.x.; Askari FK. Molecular mechanism of hepatocellular injury in alpha 1 antitrypsin deficiency. Hepatology. 1995;21(6):1745–1747. doi:10.1002/hep.1840210638.; Strange C, Dickson R, Carter C, et al. Genetic testing for alpha1-antitrypsin deficiency. Genet Med. 2004;6(4):204–210. doi:10.109701.GIM.0000132669.09819.79.; Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996;153(2):530–534. doi:10.1164/ajrccm.153.2.8564092.; Fregonese L, Stolk J. Hereditary alpha-1-antitrypsin deficiency and its clinical consequences. Orphanet J Rare Dis. 2008;3:16. doi:10.1186/1750-1172-3-16.; McElvaney NG, Stoller JK, Buist AS, et al. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1- Antitrypsin Deficiency Registry Study Group. Chest. 1997;111(2):394–403. doi:10.1378/chest.111.2.394.; Needham M, Stockley RA. Alpha 1-antitrypsin deficiency. 3: Clinical manifestations and natural history. Thorax. 2004;59(5): 441–445. doi:10.1136/thx.2003.006510.; Katz RM, Lieberman J, Siegel SC. Alpha-1 antitrypsin levels and prevalence of Pi variant phenotypes in asthmatic children. J Allergy Clin Immunol. 1976;57(1):41–45. doi:10.1016/0091-6749(76)90077-4.; Bruttmann G. [Reagin asthma and familial alpha-1antitrypsin deficiency. (In French).] Nouv Presse Med. 1974;3(10):589–591.; Bruttmann G. [Asthma associated with a familial deficiency in alpha-1-antitrypsin. (In French).] Revue francaise d’allergologie. 1973;13(4):411–418 doi:10.1016/S0035- 2845(73)80062-9.; Browne RJ, Mannino DM, Khoury MJ. Alpha 1-antitrypsin deficiency deaths in the United States from 1979–1991. An analysis using multiple-cause mortality data. Chest. 1996;110(1):78–83. doi:10.1378/chest.110.1.78.; Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med. 1976;294(24): 1316–1321. doi:10.1056/NEJM197606102942404.
-
5Electronic Resource